A Phase 3 interventional study of estradiol, 10 mcg in Menopause and Postmenopausal Vaginal Atrophy, sponsored by Novo Nordisk A/S. Completed at 42 sites in 7 countries. Open to female participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-15.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial is conducted in Europe. The purpose of this study is to evaluate endometrial safety of intravaginal estradiol (Vagifem®) in healthy postmenopausal women having atropic vaginitis.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One 10 mcg (microgram) vaginal tablet of intravaginal estradiol (Vagifem®) once daily for two weeks followed by one 10 mcg vaginal tablet twice weekly for 50 weeks
Drug: estradiol, 10 mcg
Tablets, administered intravaginally twice weekly
Endometrial Hyperplasia Based on Histological Assessment of Endometrial Biopsies
The endometrial hyperplasia rate was calculated based on the number of patients with endometrial hyperplasia/endometrial carcinoma divided by the total number of subjects with interpretable biopsies at Week 52.
Time frame: Week 52
Transvaginal Ultrasound: Endometrial Thickness
Transvaginal ultrasounds were performed at Baseline (Week 0) and Week 52, or at the time of withdrawal in the case of a subject's premature discontinuation. Endometrial thickness, measured (double layer) in mm, were lesser than 4 mm for entry into the trial.
Time frame: Week 0, week 52
40 sites in Czech Republic, Denmark, Finland, France, Hungary, Norway, and Sweden
| Milestone | Vagifem® 10 mcg |
|---|---|
| Started | 336 |
| Completed | 292 |
| Not completed | 44 |
The endometrial hyperplasia rate was calculated based on the number of patients with endometrial hyperplasia/endometrial carcinoma divided by the total number of subjects with interpretable biopsies at Week 52.
| percentage of participants | Vagifem® 10 mcg |
|---|---|
| Simple hyperplasia without atypia | 0 |
| Simple hyperplasia with atypia | 0 |
| Complex hyperplasia without atypia | 0 |
| Complex hyperplasia with atypia | 0 |
| Carcinoma | 0 |
Transvaginal ultrasounds were performed at Baseline (Week 0) and Week 52, or at the time of withdrawal in the case of a subject's premature discontinuation. Endometrial thickness, measured (double layer) in mm, were lesser than 4 mm for entry into the trial.
| mm | Vagifem® 10 mcg |
|---|---|
| Baseline | 2.04 ± 0.9 |
| Week 52 | 1.94 ± 0.9 |
Collected over Adverse events were collected over a time frame of 12 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vagifem® 10 mcg | — | 14/336 (4.2%) | 17/336 (5.1%) |
| Event | Vagifem® 10 mcg |
|---|---|
| Radius fractureInjury, poisoning and procedural complications | 2/336 |
| Myocardial infarctionCardiac disorders | 1/336 |
| Abdominal painGastrointestinal disorders | 1/336 |
| MelaenaGastrointestinal disorders | 1/336 |
| CholelithiasisHepatobiliary disorders | 1/336 |
| Forearm fractureInjury, poisoning and procedural complications | 1/336 |
| Post procedural haematomaInjury, poisoning and procedural complications | 1/336 |
| Spinal column stenosisMusculoskeletal and connective tissue disorders | 1/336 |
| Colon adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/336 |
| Leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/336 |
| Event | Vagifem® 10 mcg |
|---|---|
| NasopharyngitisInfections and infestations | 17/336 |
| Age, Continuous(years) | Vagifem® 10 mcg |
|---|---|
| Mean | 59.5 ± 6.2 |
| Sex: Female, Male(Participants) | Vagifem® 10 mcg |
|---|---|
| Female | 336 |
| Male | 0 |
| Race (NIH/OMB)(Participants) | Vagifem® 10 mcg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 296 |
| More than one race | 0 |
| Unknown or Not Reported | 39 |
| Body Mass Index (BMI)(kg/m^2) | Vagifem® 10 mcg |
|---|---|
| Mean | 24.6 ± 3.4 |
The record gives a start of Jan 2007, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol